Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, announce that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex.
Read the full article: Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. //
Source: https://www.globenewswire.com/news-release/2025/04/08/3057613/0/en/Onconetix-Signs-Letter-of-Intent-for-Potential-Business-Combination-with-Ocuvex-Therapeutics-Inc.html